← board
NEOG
distress 1/10 · well-funded / low risk$9.54-3%today-16% from 52w high
Revenue
$645M
Liquidity
$160M
Runway
—
Shares 1y
+0%
Price & events
-3.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.9%
1D
-7.6%
1W
+8.1%
1M
+2.1%
3M
-2.6%
6M
+88.6%
1Y
-43.3%
2Y
-78.0%
5Y
-75.7%
All
Overview
- Market Cap
- $2.08B
- Enterprise Value
- $2.71B
- Volume
- 116.49K
- 52 Week Range
- $4.65 – $11.33
- Total Shares
- 217.67M
- Float Shares
- 216.47M
- Short %
- 6.44%
- % Held by Insiders
- 0.95%
- % Held by Institutions
- 113.83%
- RVOL
- 0.07x
- Beta
- 1.79
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-07-30earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $12 (+26% upside) · 3 analysts
- 2026-01-12Piper SandlerNeutral
- 2026-01-09GuggenheimBuy
- 2025-12-10CJS SecuritiesMarket Perform → Market Outperform
- 2025-10-16Piper SandlerNeutral
- 2025-09-29CJS SecuritiesMarket Perform
- 2025-07-29William BlairOutperform → Market Perform
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.